[CAS NO. 1390654-28-0]  KRN2bromide

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1390654-28-0]

Catalog
HY-112125A
Brand
MCE
CAS
1390654-28-0

DESCRIPTION [1390654-28-0]

Overview

MDL-
Molecular Weight524.38
Molecular FormulaC27H23BrFNO4
SMILESCOC1=C(OC)C2=C[N+]3=C(C(C(CC3)=C4)=CC5=C4OCO5)C(CC6=CC=CC=C6F)=C2C=C1.[Br-]

For research use only. We do not sell to patients.

1 Publications Citing Use of MCE


Summary

KRN2 (bromide) is a selective inhibitor of nuclear factor of activated T cells (NFAT5) , with an IC 50 of 0.1 μM.


IC50 & Target

IC50: 100 nM (NFAT5) [1]


In Vitro

KRN2 selectively suppresses the expression of pro-inflammatory genes, including Nos2 and Il6, without hampering high-salt-induced NFAT5 and its target gene expressions [1] .
KRN2 dose-dependently inhibits the NF-κB p65 binding to Nfat5 promoter 1 and directly blocks the interaction between NF-κB p65 and its DNA binding sequence in the upstream site (base pairs -3000 to +1) of Nfat5 exon 1 [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


In Vivo

KRN2 (3 mg/kg, i.p., daily for 2 weeks) effectively suppresses AIA in which innate immune cells play a predominant role [1] .
KRN2 (3 mg/kg, i.p., daily) effectively suppresses CIA as well as AIA in mice, decreasing the production of pro-inflammatory cytokines and autoantibodies as well as macrophage infiltration [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 8-week-old C57BL/6 mice injected intradermally with 2 mg of complete Freund's adjuvant [1] .
Dosage: 3 mg/kg.
Administration: Peritoneally (i.p.) daily for 2 weeks.
Result: Effective in suppressing AIA.
Animal Model: 8-week-old DBA/1Jmice immunized with bovine type II collagen [1] .
Dosage: 3 mg/kg.
Administration: Peritoneally (i.p.) daily.
Result: Effective in suppressing CIA as well as AIA in mice, decreasing the production of pro-inflammatory cytokines and autoantibodies as well as macrophage infiltration.

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)


Solvent & Solubility

In Vitro:

DMSO : 18.33 mg/mL ( 34.96 mM ; Need ultrasonic)

H 2 O : 1.1 mg/mL ( 2.10 mM ; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.9070 mL 9.5351 mL 19.0701 mL
5 mM 0.3814 mL 1.9070 mL 3.8140 mL
10 mM 0.1907 mL 0.9535 mL 1.9070 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 1.83 mg/mL (3.49 mM); Clear solution

  • 2.

    Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 1.83 mg/mL (3.49 mM); Clear solution

  • 3.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 1.83 mg/mL (3.49 mM); Clear solution

* All of the co-solvents are available by MCE.